Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force
| Autor: | Beiske, K, Burchill, SA, Cheung, IY, Hiyama, E, Seeger, RC, Cohn, SL, Pearson, ADJ, Matthay, KK, International neuroblastoma Risk Group Task Force |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
International neuroblastoma Risk Group Task Force
Consensus minimal disease Health Planning Guidelines Advisory Committees Oncology and Carcinogenesis Neoplastic Cells Sensitivity and Specificity Specimen Handling neuroblastoma QRT-PCR Rare Diseases Bone Marrow Stem Cell Research - Nonembryonic - Human Circulating INRG Humans Oncology & Carcinogenesis Cancer Pediatric Transplantation immunocytology Reverse Transcriptase Polymerase Chain Reaction Neurosciences Reference Standards Stem Cell Research Immunohistochemistry Residual Neoplastic Stem Cells Public Health and Health Services Neoplasm Algorithms |
| Zdroj: | British journal of cancer, vol 100, iss 10 |
| Popis: | Disseminating disease is a predictive and prognostic indicator of poor outcome in children with neuroblastoma. Its accurate and sensitive assessment can facilitate optimal treatment decisions. The International Neuroblastoma Risk Group (INRG) Task Force has defined standardised methods for the determination of minimal disease (MD) by immunocytology (IC) and quantitative reverse transcriptase-polymerase chain reaction (QRT-PCR) using disialoganglioside G(D2) and tyrosine hydroxylase mRNA respectively. The INRG standard operating procedures (SOPs) define methods for collecting, processing and evaluating bone marrow (BM), peripheral blood (PB) and peripheral blood stem cell harvest by IC and QRT-PCR. Sampling PB and BM is recommended at diagnosis, before and after myeloablative therapy and at the end of treatment. Peripheral blood stem cell products should be analysed at the time of harvest. Performing MD detection according to INRG SOPs will enable laboratories throughout the world to compare their results and thus facilitate quality-controlled multi-centre prospective trials to assess the clinical significance of MD and minimal residual disease in heterogeneous patient groups. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|